Actively Recruiting
A Study of Chinese Congenital Bicuspid Aortic Valve
Led by Ruijin Hospital · Updated on 2025-02-03
500
Participants Needed
1
Research Sites
571 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Pervious studies indicated that the prevalence of bicuspid aortic valve（BAV） might be higher in China. There is a familial predisposition to the development of BAV. The study analyzed epidemiological data on selected BAV and established a BAV cohort to observe disease progression and treatment outcomes.
CONDITIONS
Official Title
A Study of Chinese Congenital Bicuspid Aortic Valve
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 14 to 60 years
- Confirmed diagnosis of bicuspid aortic valve by imaging (echocardiography, aortic CTA, cardiac magnetic resonance, etc.)
- Patients informed about the study and who signed an ethics committee-approved informed consent form
You will not qualify if you...
- Poor compliance or inability to complete required follow-up visits
- Rheumatic heart valve disease or other organic valve diseases
- Hyperthyroidism, severe anemia, or other conditions significantly affecting hemodynamics
- Other conditions deemed exclusionary by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin hospital, Shanghai JiaoTong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
W
Wenli Zhang, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here